Discussing whether the government should have a bigger hand in regulating pharma companies with Michael Tanner, Cato Institute Dir. of Health & Welfare Studies; Peter Lurie, Public Citizen's Health Research Group Deputy Director; and CNBC's Michelle Caruso-Cabrera
Topics:
Pharmaceuticals | Social Security | Biotechnology
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT